NCT04009772

Brief Summary

Compare between cefepime versus routine antibiotics as a prophylactic antibiotic during emergency cesarean section in a tertiary center of obstetric care

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 1, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 5, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

July 5, 2019

Status Verified

July 1, 2019

Enrollment Period

7 months

First QC Date

July 1, 2019

Last Update Submit

July 3, 2019

Conditions

Keywords

Cefepime, Cefuroxime, Metronidazole, Cesarean, Intrapartum

Outcome Measures

Primary Outcomes (1)

  • Incidence of surgical site wound infection

    Examining the wound after one week of the surgery to detect any infection

    one week

Study Arms (2)

"Cefepime" , "Maxipime®" 1 gm

ACTIVE COMPARATOR

Patient will receive "Cefepime" ,"Maxipime®" 1 gm IV during cesarean section just before skin incision

Drug: Cefepime

"Cefuroxime", "Zinnat®" 1gm plus "metronidazole"Flagyl®" 500

ACTIVE COMPARATOR

Patient will receive "Cefuroxime", "Zinnat®" 1gm ,and "metronidazole"Flagyl®" 500 IV; just before skin incision for emergency cesarean section

Drug: Cefuroxime plus Metronidazole

Interventions

Antibiotic prophylaxis

Also known as: Maxipime
"Cefepime" , "Maxipime®" 1 gm

Antibiotic prophylaxis

Also known as: Zinnat plus Flagyl
"Cefuroxime", "Zinnat®" 1gm plus "metronidazole"Flagyl®" 500

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • intrapartum caesarean section

You may not qualify if:

  • evidence of infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

RECRUITING

MeSH Terms

Conditions

Wound Infection

Interventions

CefepimeCefuroximeMetronidazolecefuroxime axetil

Condition Hierarchy (Ancestors)

Infections

Intervention Hierarchy (Ancestors)

Cephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNitroimidazolesNitro CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Central Study Contacts

Abdalmageed Abdalmageed

CONTACT

Osama Abdalmageed

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant of Obstetrics and gynecology

Study Record Dates

First Submitted

July 1, 2019

First Posted

July 5, 2019

Study Start

July 1, 2019

Primary Completion

February 1, 2020

Study Completion

March 1, 2020

Last Updated

July 5, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations